MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Out-licensing

Novel Therapeutic Approach to the Prevention and Treatment of Staphylococcus aureus Infections

WORLDiscoveries
A suite of highly specific, proprietary bacterial drug targets in staphylococcus aureus, that can be used individually or as a group to develop small molecule or peptide drug leads with powerful anti-infectives properties.

Mechanism of action

Inhibition of bacterial iron uptake mechanisms as an effective means to abrogate bacterial infection

Full description

Keywords: Anti-Infectives, Gram-Positive Pathogens, Antibiotic Resistance, Hospital Related Infections; Bacterial Iron uptake

DESCRIPTION OF THE INVENTION: The present technology suite is based on the identification of a suite of highly specific, proprietary bacterial drug targets in staphylococcus aureus, that can be used individually or as a group to develop small molecule or peptide drug leads with powerful anti-infectives properties. The underlying mechanism of action is to inhibit bacterial iron uptake mechanisms and thus to starve the pathogen of its critical food source. One target (UWO-AE-008) is an iron-regulated, nine gene operon (sbn) whose products are involved in the synthesis of a siderophore (secreted iron-chelating agent) in S. aureus. Expression of the sbn operon is crucial for iron-restricted growth of S. aureus both in vivo and in vitro. Other targets include the SirABC protein complex (UWO-AE-028) which is used to transport the S. aureus siderophore and the IsdABC proteins (UWO-AE-009) which are anchored to the cell wall of S. aureus and are used in the binding of heme.

BACKGROUND: Staphylococci are capable of causing a diverse array of diseases, ranging in severity from food poisoning and urinary tract infections to toxic shock syndrome, bacteremia and endocarditis. Arguably the most important cause of life-threatening bacterial infections in the world, Staphylococcus aureus is the leading cause of hospital-related diseases in the United States, the most prevalent pathogen isolated from skin and soft-tissue infections, one of the four leading causes of food-borne illness, and one of the most common agents of infective endocarditis. The recent identification of isolates of S. aureus resistant to the antibiotic vancomycin, considered the last line of defense against bacterial infection, further underscores the importance of identifying novel therapeutic targets against this important pathogen. Bacterial iron acquisition systems have received recent attention as a promising therapeutic target. This is due to the fact that the majority of bacterial pathogens require iron to infect. Iron is the only limiting nutrient to bacterial growth inside the human host and iron limitation is an important innate human defense against bacterial infection.

POTENTIAL ADVANTAGES/USES: This technology presents a unique tool to identify and develop novel classes of drugs and methodologies to prevent and treat S. aureus infections. It will be of interest to pharmaceutical and biotechnology companies developing diagnostic tools, vaccines and/or therapeutics in the area of hospital related infections, treatment resistant pathogens, sepsis, bacteremia and infectious endocarditis. 

DEVELOPMENTAL STAGE: Preclinical proof of principle

REF: UWO-AE-008, UWO-AE-028 and UWO-AE-009 

Development status

Preclinical

Patent information

US and PCT applications filed.

Type of business relationship sought

This technology is available for licensing and/or collaborative approach

Licensing contact

Dr. Ting Ling
Business Development Manager, Life Sci
WORLDiscoveries™

Contact directly

Company details

WORLDiscoveries

WORLDiscoveries™ is the business development arm of London’s extensive research network and the bridge between local invention and global industry.

View profile

Related reports

Are you looking for reports related to this particular subject. Our Reports section is the best place to start.

Related items

Related categories

Clients in focus...

Get the Flash Player to see this rotator.

Partnering discussion free of charge
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us